Detalhe da pesquisa
1.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
N Engl J Med;
384(19): 1800-1809, 2021 05 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33979488
2.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Am J Respir Crit Care Med;
208(1): 13-24, 2023 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37015033
3.
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res;
21(1): 279, 2020 Oct 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33087119
4.
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Respir Res;
21(1): 265, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33050900
5.
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Respir Res;
21(1): 264, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33050928
6.
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Respir Res;
21(1): 266, 2020 Oct 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33050934
7.
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
Eur Respir J;
53(2)2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30442714
8.
Reply to Lipworth and Chan.
Am J Respir Crit Care Med;
208(2): 212-213, 2023 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37279366
9.
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
BMC Pulm Med;
19(1): 129, 2019 Jul 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31315668
10.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
JAMA;
317(18): 1844-1853, 2017 05 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28492898
11.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Lancet Respir Med;
11(5): 425-438, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36702146
12.
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Curr Med Res Opin;
39(10): 1395-1405, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37583267
13.
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Immunotherapy;
15(16): 1327-1340, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37772607
14.
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
Immunotherapy;
10(6): 473-490, 2018 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29536781
15.
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
Lancet Respir Med;
6(7): 511-525, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29792288
16.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
J Clin Oncol;
33(3): 244-50, 2015 Jan 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25366685